# Donor‐Derived T‐Cell Redirection With Epcoritamab Achieving Complete Response After Early Post‐Allo‐HSCT Relapse of DLBCL

## TL;DR

Epcoritamab, a bispecific antibody, achieved a complete response in a DLBCL patient after allogeneic stem cell transplant, suggesting it could be a safe and effective treatment for relapsed lymphoma.

## Contribution

Demonstrates the potential of donor-derived T-cell redirection with epcoritamab as a salvage therapy for DLBCL post-transplant.

## Key findings

- Epcoritamab achieved a complete response after donor T-cell engraftment in a DLBCL patient.
- Treatment did not cause severe graft-versus-host disease or cytokine release syndrome.
- Suggests enhanced antitumor efficacy with epcoritamab in the post-transplant setting.

## Abstract

Epcoritamab, a bispecific CD3×CD20 antibody, offers a promising treatment for relapsed diffuse large B‐cell lymphoma (DLBCL). Its efficacy and safety after allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remain unclear.

In a 64‐year‐old man with relapsed DLBCL, epcoritamab showed limited efficacy, achieving stable disease prior to allo‐HSCT; nevertheless, re‐administration after donor T‐cell engraftment resulted in a complete response without severe graft‐versus‐host disease or cytokine release syndrome.

This observation suggests that donor‐derived T‐cell redirection with epcoritamab may enhance antitumor efficacy while maintaining safety in the post‐transplant setting, supporting its potential as a salvage therapy for relapsed DLBCL post‐allo‐HSCT.